Skip to main
TRVI

TRVI Stock Forecast & Price Target

TRVI Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Trevi Therapeutics is likely to see success and positive clinical results in its upcoming late-stage trials for Haduvio, which could lead to its development and eventual commercialization for the treatment of IPF cough, RCC, and non-IPF ILD. The company has demonstrated strong clinical results for Haduvio in multiple cough indications and has a large potential market opportunity. Investor attention may also be drawn to the upcoming readout of GSK's camlipixant trial, which could have a beneficial impact on TRVI. The company has a strong cash position and is well-positioned to continue advancing Haduvio towards commercialization, with potential partnerships in the future to address broader market opportunities.

Bears say

Trevi Therapeutics is facing significant financing and regulatory risks as they continue to incur high operating expenses for the clinical development of Haduvio in multiple indications, including IPF cough and refractory chronic cough. Despite a trend toward reduced cough frequency, most patients have reported unsuccessful attempts at treating their cough, potentially hindering the success of Haduvio. Additionally, the company will need additional capital to support the development and potential commercialization of Haduvio, adding to the financial risk of investing in this stock.

TRVI has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Trevi Therapeutics Inc (TRVI) Forecast

Analysts have given TRVI a Strong Buy based on their latest research and market trends.

According to 11 analysts, TRVI has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Trevi Therapeutics Inc (TRVI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.